252 related articles for article (PubMed ID: 31336293)
1. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States.
Davis CS; Carr DH
Int J Drug Policy; 2019 Nov; 73():42-48. PubMed ID: 31336293
[TBL] [Abstract][Full Text] [Related]
2. Comparing Canadian and United States opioid agonist therapy policies.
Priest KC; Gorfinkel L; Klimas J; Jones AA; Fairbairn N; McCarty D
Int J Drug Policy; 2019 Dec; 74():257-265. PubMed ID: 30765118
[TBL] [Abstract][Full Text] [Related]
3. Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction.
Calcaterra SL; Bach P; Chadi A; Chadi N; Kimmel SD; Morford KL; Roy P; Samet JH
J Gen Intern Med; 2019 Jun; 34(6):1039-1042. PubMed ID: 30729416
[TBL] [Abstract][Full Text] [Related]
4. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
[TBL] [Abstract][Full Text] [Related]
5. Deploying science to change hearts and minds: Responding to the opioid crisis.
Walsh SL; Long KQX
Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
[TBL] [Abstract][Full Text] [Related]
6. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
Ferrara MM
Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
[No Abstract] [Full Text] [Related]
7. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
8. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
Kelty E; Hulse G
Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
[TBL] [Abstract][Full Text] [Related]
9. Underutilization of medications to treat opioid use disorder: What role does stigma play?
Allen B; Nolan ML; Paone D
Subst Abus; 2019; 40(4):459-465. PubMed ID: 31550201
[TBL] [Abstract][Full Text] [Related]
10. Opioid Use Disorder and Pregnancy.
O'Donnell FT; Jackson DL
Mo Med; 2017; 114(3):181-186. PubMed ID: 30228577
[TBL] [Abstract][Full Text] [Related]
11. Comparison between buprenorphine provider availability and opioid deaths among US counties.
Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R
J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537
[TBL] [Abstract][Full Text] [Related]
12. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
13. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
[TBL] [Abstract][Full Text] [Related]
14. Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder.
Patrick SW; Richards MR; Dupont WD; McNeer E; Buntin MB; Martin PR; Davis MM; Davis CS; Hartmann KE; Leech AA; Lovell KS; Stein BD; Cooper WO
JAMA Netw Open; 2020 Aug; 3(8):e2013456. PubMed ID: 32797175
[TBL] [Abstract][Full Text] [Related]
15. Development of a Cascade of Care for responding to the opioid epidemic.
Williams AR; Nunes EV; Bisaga A; Levin FR; Olfson M
Am J Drug Alcohol Abuse; 2019; 45(1):1-10. PubMed ID: 30675818
[TBL] [Abstract][Full Text] [Related]
16. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
17. Improving Rural Access to Opioid Treatment Programs.
Johnson Q; Mund B; Joudrey PJ
J Law Med Ethics; 2018 Jun; 46(2):437-439. PubMed ID: 30146991
[TBL] [Abstract][Full Text] [Related]
18. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
[TBL] [Abstract][Full Text] [Related]
19. Methadone's Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction).
Suen LW; Incze M; Simon C; Englander H; Bratberg J; Groves Scott G; Winograd R
Subst Use Addctn J; 2024 Jul; 45(3):337-345. PubMed ID: 38804606
[TBL] [Abstract][Full Text] [Related]
20. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
